Q2 2025 HLS Therapeutics Inc Earnings Call Transcript
Key Points
- HLS Therapeutics Inc (HLTRF) reported a 21% growth in adjusted EBITDA for Q2 and a 29% increase year-to-date, reflecting strong operational performance.
- Cash from operations grew by more than 80% in Q2 and almost 150% year-to-date, indicating improved cash flow management.
- The company is expanding its cardiovascular portfolio with the upcoming launch of Nexletol and Nexlezette, which are expected to significantly increase the size of their cardiovascular business.
- HLS Therapeutics Inc (HLTRF) has made significant progress in deleveraging its balance sheet, reducing debt, and lowering interest expenses.
- The company has successfully transitioned Vascepa sales from Pfizer, achieving positive contributions to adjusted EBITDA for three consecutive quarters.
- Revenue for Q2 was slightly down compared to the previous year, impacted by FX headwinds and a decline in royalty revenue.
- Clozaril sales in Canada were below expectations due to lighter than expected unit volumes purchased by hospitals and wholesalers.
- The company experienced short-term disruptions in customer engagement due to personnel changes in the sales force, affecting Vascepa's performance.
- Unit demand for Vascepa was slightly softer than forecasted, although net sales growth remained within guidance.
- Prelaunch spending for new products like Nexletol and Nexlezette will require several hundred thousand dollars, with additional operational expenses anticipated in 2026.
Good morning, and welcome to the Q2 twenty twenty five Financial Results Conference Call for HLS Therapeutics. At this point, I would like to turn the call over to David Mason, Investor Relations, for the introductory remarks.
Good morning, everyone, and thank you for joining us today. With me on the call is Craig Millian, Chief Executive Officer John Hanna, Chief Financial Officer and Brian Walsh, Chief Commercial Officer. Earlier this morning, we issued a news release announcing our financial results for the three and six months ended 06/30/2025. This news release, along with our MD and A and financial statements, is available on our website and on SEDAR plus Please note that slides accompanying todayâs call can be viewed by the webcast, a link to which is available in our earnings press release and at our website on the Events and Presentations page. Certain matters discussed in todayâs conference call or answers that may be given to questions could constitute forward looking statements.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
